With dupilumab’s recent FDA approval as the first biologic therapy for COPD patients, and ongoing clinical trials reassessing IL-5 agents, more studies are needed to assess the benefits and risks of biologics. The gene discussed is IL5; the disease is chronic obstructive pulmonary disease.